What is the 13F Pro Quality Score for NBIX?

13F Pro ranks NEUROCRINE BIOSCIENCES INC (NBIX) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View NBIX's current score at https://13fpro.ai/research/NBIX (free sign-up required for the full ranking).

Which hedge funds own the most NBIX stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of NBIX include BlackRock,, DODGE & COX, AQR CAPITAL MANAGEMENT. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/NBIX as soon as new 13F filings post.

Where does 13F Pro source NBIX data?

All NEUROCRINE BIOSCIENCES INC fundamentals and ownership data come directly from SEC EDGAR. NEUROCRINE BIOSCIENCES INC files with the SEC under CIK 914475. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is NBIX in?

NEUROCRINE BIOSCIENCES INC (NBIX) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

What drives NBIX's revenue?

Per NEUROCRINE BIOSCIENCES INC's latest 10-Q filed with the SEC on 2026-05-05, the biggest revenue drivers are: INGREZZA net product sales ($656.9M, +20.5% YoY); CRENESSITY net product sales ($153.3M, from $14.5M YoY); Collaboration revenues ($3.5M, -60.7% YoY). Figures are extracted from the filing text and machine-verified against the document. Full breakdown at https://13fpro.ai/research/NBIX.

What are NBIX's largest expenses?

NEUROCRINE BIOSCIENCES INC's latest 10-Q reports these as the largest expense items: Cost of revenues ($13.8M, +50.0% YoY); Acquired in-process research and development ($21.2M, from $0.1M YoY). Sourced directly from SEC EDGAR filing text for Q1 2026 (quarter ended March 31, 2026).

How often is NBIX research updated on 13F Pro?

NBIX's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

NEUROCRINE BIOSCIENCES INC(NBIX)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 914475 NBIX stock profile & AI dashboard →

13F Pro Quality Score

75.4/100

Rank #128 of 2,879 stocksTOP 5%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

83.5/100

Profitability

85.2/100

Balance Sheet

88.7/100

Earnings Quality

91.7/100

Free Cash Flow

75.4/100

Institutional Flow

22.3/100

Revenue Scale

69.1/100

Dilution Risk

20.3/100

NBIX Stock Analysis & AI Quality Score

AI stock analysis and institutional research for NEUROCRINE BIOSCIENCES INC (NBIX), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores NBIX at 75.4/100 on a 32-signal composite quality model, placing it at rank #128 of 2,879 stocks — the top 5% of the AI-ranked universe. NBIX scores in the top quartile across earnings quality (91.7), balance sheet strength (88.7), profitability (85.2). Areas of concern include institutional flow (22.3), which score below median versus the broader universe. Shareholder dilution risk is elevated at 20.3/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), NEUROCRINE BIOSCIENCES INC reports quarterly revenue of $814.5M, net income of $197.9M, an operating margin of 23.7%. Top institutional holders of NBIX by reported 13-F value include BlackRock,, DODGE & COX, AQR CAPITAL MANAGEMENT, based on the most recent SEC filings. NBIX trades on the Nasdaq exchange and files with the SEC under CIK 914475. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate NBIX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for NEUROCRINE BIOSCIENCES INC directly from SEC EDGAR. NEUROCRINE BIOSCIENCES INC's 13F Pro composite quality score has ranged between 8 and 89 since 2021, currently 75.4 — a declining long-term trajectory across 56 quarterly and live scoring snapshots.

✦

Fun facts about NEUROCRINE BIOSCIENCES INC

Quirks, history, and lore behind NBIX — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. biopharmaceutical company · mid-cap · listed on Nasdaq · headquartered in San Diego, California.
2
The Numbers
Annual revenue in the range of roughly $2 billion, driven almost entirely by a single blockbuster drug — a rare feat of focus in an industry that loves sprawl.
3
The History
Founded in the mid-1990s, it spent years as a quiet CNS-focused biotech before a landmark deal with AbbVie helped fund its early pipeline and put it on the map.
4
The Secret
Its core expertise is in neurological and psychiatric disorders — the kind of conditions that Big Pharma long ignored — including tardive dyskinesia and movement disorders.
5
The Lore
Its top-selling drug Ingrezza (valbenazine) was the first FDA-approved treatment specifically for tardive dyskinesia, a condition affecting millions who had been largely left behind by medicine.
6
The Giveaway
Ticker NBIX, built on Ingrezza, and quietly becoming one of neuroscience's most focused success stories — this is Neurocrine Biosciences.

▶ Think you know your stocks? Play the Daily Ticker

What's Driving NBIX's Business? Latest 10-Q Breakdown

AI-extracted from NEUROCRINE BIOSCIENCES INC's 10-Q filed 2026-05-05 — Q1 2026 (quarter ended March 31, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

Biggest Revenue Drivers

INGREZZA net product sales$656.9M+20.5% YoY

Driven primarily by volume growth and record new prescriptions on strong patient demand.

CRENESSITY net product sales$153.3Mfrom $14.5M YoY

First-in-class treatment for CAH launched in U.S. December 2024; reflects full quarter of commercial sales in Q1 2026.

Collaboration revenues$3.5M-60.7% YoY

Primarily royalties on AbbVie net sales of elagolix and Tanabe Pharma net sales of valbenazine.

Largest Expense Items

Cost of revenues$13.8M+50.0% YoY

Increased royalties payable on net product sales of CRENESSITY and increased total net product sales.

Acquired in-process research and development$21.2Mfrom $0.1M YoY

Increased payments for upfront fees in connection with collaborations, including $22.5M milestone to Nxera for NBI-1117570 Phase 2 initiation.

Watch Items from the Filing

Pending acquisition of Soleno Therapeutics for ~$2.9B in cash (commenced April 20, 2026); HSR waiting period expired April 27, 2026; transaction expected to close Q2 2026 but dependent on majority tender and closing conditions; would significantly reduce cash and investment balances.
DOJ civil investigative demand received August 2025 regarding INGREZZA sales and marketing practices; investigation timing and outcome uncertain, creating legal risk and potential regulatory exposure.
INGREZZA qualifies for small biotech exception from Medicare Drug Negotiation Program until 2027; if selected in 2029, negotiated pricing would apply, constrained by 'short monopoly' price ceiling; loss of exemption could materially impact revenues and formulary coverage.
Completed sale of Neurocrine Group Limited on January 21, 2026 for $63.2M cash, recognizing $28.6M pre-tax gain; divestiture reduces diversification but provides liquidity for Soleno acquisition.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →Share on X

Revenue

Q1 2026

$814.5M

Net Income

Q1 2026

$197.9M

Free Cash Flow

Q1 2026

$136.7M

Operating Margin

Q1 2026

23.7%

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+21.4% YoY

$2.86BFY 2025

FY22 $1.49BFY23 $1.89BFY24 $2.36BFY25 $2.86B

Net Income

+40.2% YoY

$478.6MFY 2025

FY22 $154.5MFY23 $249.7MFY24 $341.3MFY25 $478.6M

Operating Income

+8.5% YoY

$619.1MFY 2025

FY22 $249.0MFY23 $250.9MFY24 $570.5MFY25 $619.1M

EPS (Diluted)

+41.9% YoY

$4.67FY 2025

FY22 $1.56FY23 $2.47FY24 $3.29FY25 $4.67

Total Assets

+24.5% YoY

$4.63BFY 2025

FY22 $2.37BFY23 $3.25BFY24 $3.72BFY25 $4.63B

Op. Cash Flow

+31.5% YoY

$782.7MFY 2025

FY22 $339.4MFY23 $389.9MFY24 $595.4MFY25 $782.7M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$2.86B +21.4%	$2.36B +24.8%	$1.89B +26.8%	$1.49B +31.3%	$1.13B +8.4%	$1.05B
Net Income	$478.6M +40.2%	$341.3M +36.7%	$249.7M +61.6%	$154.5M +72.4%	$89.6M -78.0%	$407.3M
Operating Income	$619.1M +8.5%	$570.5M +127.4%	$250.9M +0.8%	$249.0M +142.9%	$102.5M -37.1%	$163.0M
EPS (Diluted)	$4.67 +41.9%	$3.29 +33.2%	$2.47 +58.3%	$1.56 +69.6%	$0.92 -77.9%	$4.16
Total Assets	$4.63B +24.5%	$3.72B +14.4%	$3.25B +37.3%	$2.37B +14.3%	$2.07B +19.5%	$1.73B
Operating Cash Flow	$782.7M +31.5%	$595.4M +52.7%	$389.9M +14.9%	$339.4M +32.3%	$256.5M +12.3%	$228.5M

AI Insight: NBIX Financial Trends

NBIX delivered its highest-ever quarterly revenue of $814M in Q1 2026, while net income surged to $198M — the strongest Q1 profit in the dataset.

• Revenue grew 38% year-over-year from $590M in Q2 2024 to $814M in Q1 2026, with consistent sequential gains since Q1 2025.

• Net income expanded dramatically from $8M in Q1 2025 to $198M in Q1 2026, a ~24x year-over-year improvement.

• Equity strengthened from $2,509M in Q2 2024 to $3,407M in Q1 2026, reflecting six quarters of cumulative earnings retention.

• Operating cash flow hit $388M in Q4 2025 before normalizing to $146M in Q1 2026, consistent with typical seasonal Q1 patterns.

⚠ Q1 operating income of $193M lagged Q4 2025's $211M despite higher revenue — operating margin compression warrants monitoring.

⚠ Total debt data is absent across all periods; leverage position and interest burden remain unassessable.

⚠ Q1 2025 net income collapsed to $8M — recurring seasonal cost spikes could cap annual earnings if not managed.

AI Insight: NBIX Ratio Trends

Q3 2025 peak margins and ROIC of 31.8% confirm a strong underlying business, but Q1 profitability remains structurally weak — a recurring seasonal pattern to watch.

• ROIC peaked at 31.8% in Q3 2025, up from 21.9% in Q4 2024, signaling strong capital efficiency at mid-year.

• Net profit margin surged to 26.4% in Q3 2025 and held at 24.3% in Q1 2026, well above Q2 2024's 11.0%.

• Q1 2025 operating margin collapsed to 4.1% and ROIC to 3.7%, mirroring a sharp seasonal or one-off earnings trough.

⚠ Q1 profitability troughs repeatedly — Q1 2026 OpMargin of 23.7% vs. Q3 2025's 30.1% warrants scrutiny for recurring cost spikes.

⚠ D/E data is entirely absent; leverage profile cannot be assessed, leaving balance sheet risk unquantified.

Get alerted when NBIX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for NEUROCRINE BIOSCIENCES INC including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of NBIX

BlackRock, Inc.
$1.8B13,385,607 sh
DODGE & COX
$719.4M5,461,037 sh
AQR CAPITAL MANAGEMENT LLC
$650.7M4,938,967 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$622.6M4,726,344 sh
VANGUARD CAPITAL MANAGEMENT LLC
$594.4M4,511,904 sh
STATE STREET CORP
$573.7M4,354,526 sh
TWO SIGMA INVESTMENTS, LP
$403.2M3,060,570 sh
RENAISSANCE TECHNOLOGIES LLC
$318.7M2,418,897 sh
GEODE CAPITAL MANAGEMENT, LLC
$280.8M2,136,672 sh
BNP Paribas Asset Management Holding S.A.
$196.8M1,493,813 sh

Fund	Value	Shares
BlackRock, Inc.	$1.8B	13,385,607
DODGE & COX	$719.4M	5,461,037
AQR CAPITAL MANAGEMENT LLC	$650.7M	4,938,967
VANGUARD PORTFOLIO MANAGEMENT LLC	$622.6M	4,726,344
VANGUARD CAPITAL MANAGEMENT LLC	$594.4M	4,511,904
STATE STREET CORP	$573.7M	4,354,526
TWO SIGMA INVESTMENTS, LP	$403.2M	3,060,570
RENAISSANCE TECHNOLOGIES LLC	$318.7M	2,418,897
GEODE CAPITAL MANAGEMENT, LLC	$280.8M	2,136,672
BNP Paribas Asset Management Holding S.A.	$196.8M	1,493,813

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put NBIX on your watchlist

Track score changes the day NEUROCRINE BIOSCIENCES INC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is NBIX a good stock to buy?

13F Pro's AI-powered analysis of NEUROCRINE BIOSCIENCES INC (NBIX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for NBIX are available on the NBIX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own NBIX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling NBIX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of NEUROCRINE BIOSCIENCES INC's investment landscape.